Ramjist Joshua K, Dubljevic Tamara, Lapidus-Krol Eveline, Grace Rachael F, Heeney Matthew M, Oni Morohuntodun O, Towerman Alison, Davidoff Andrew, Takemoto Clifford, Brown Rebeccah L, Brungardt Joseph, Beaman Makenzie, Rice Henry E, Nichols Shari, Saadai Payam, Carcao Manuel, Langer Jacob C
Division of General & Thoracic Surgery, The Hospital for Sick Children, Toronto, ON, Canada; Department of Surgery, The University of Toronto, Toronto, ON, Canada.
Division of General & Thoracic Surgery, The Hospital for Sick Children, Toronto, ON, Canada; Department of Surgery, The University of Toronto, Toronto, ON, Canada.
J Pediatr Surg. 2025 Apr;60(4):162229. doi: 10.1016/j.jpedsurg.2025.162229. Epub 2025 Jan 30.
Hereditary Spherocytosis (HS) is a common genetic hematological disorder causing a life-long hemolytic anemia, with sequela of hemolysis. Children with severe HS commonly undergo partial or total splenectomy (PS, TS); PS confers the theoretical advantage of maintaining splenic immune function, but may be associated with regrowth, ongoing hemolysis, and need for completion splenectomy. HS can be caused by 5 different pathogenic gene variants. A rare and severe form is caused by homozygous/compound heterozygous mutations in the SPTA1 gene, coding for alpha spectrin. We hypothesized this form of HS is associated with worse outcomes following PS.
Following REB approval, a retrospective chart review of children with HS undergoing PS between 2000 and 2023 was conducted across 7 sites in the USA and Canada. Pre- and post-operative hematological values and need for completion splenectomy were analyzed. P < 0.05 was significant.
Of 51 eligible patients, 10 had SPTA and 41 had non-SPTA1 HS. The SPTA1 group underwent PS at a younger age to non-SPTA1 (5.1 vs 9.6 yr, p = 0.003), and had lower pre-operative hemoglobin (86.2 vs 98.8 g/L, p = 0.04). There were no differences between groups regarding peri-operative surgical or hematological outcomes. The SPTA1 group required completion splenectomy at a higher rate than the non-SPTA1 group (70.0 % vs 24.4 %, p = 0.01).
Children with SPTA1 HS are more likely to require completion splenectomy following PS than children with other HS-causing mutations. These results support the role of genetic testing to permit an evidence-based individualized approach to patient selection for partial vs. total splenectomy.
III.
遗传性球形红细胞增多症(HS)是一种常见的遗传性血液系统疾病,可导致终身溶血性贫血及溶血后遗症。重度HS患儿通常接受部分或全脾切除术(PS、TS);PS在维持脾脏免疫功能方面具有理论优势,但可能与脾脏再生、持续性溶血以及需要进行补充性脾切除术有关。HS可由5种不同的致病基因变异引起。一种罕见且严重的形式是由编码α - 血影蛋白的SPTA1基因的纯合/复合杂合突变所致。我们推测这种形式的HS在PS后预后较差。
经机构审查委员会(REB)批准,对2000年至2023年间在美国和加拿大7个地点接受PS的HS患儿进行回顾性病历审查。分析术前和术后的血液学指标以及进行补充性脾切除术的必要性。P < 0.05具有统计学意义。
在51例符合条件的患者中,10例为SPTA1相关HS,41例为非SPTA1相关HS。SPTA1组接受PS的年龄比非SPTA1组更小(5.1岁对9.6岁,p = 0.003),且术前血红蛋白水平更低(86.2 g/L对98.8 g/L,p = 0.04)。两组在围手术期的手术或血液学结果方面无差异。SPTA1组进行补充性脾切除术的比例高于非SPTA1组(70.0%对24.4%,p = 0.01)。
与其他导致HS的突变患儿相比,SPTA1相关HS患儿在PS后更有可能需要进行补充性脾切除术。这些结果支持基因检测的作用,以便采用基于证据的个体化方法为部分脾切除术与全脾切除术选择患者。
III级